Loading stock data…
$80.28-11.35 (-12.39%)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Kodiak Sciences Inc. in the Healthcare sector is trading at $83.32 with a market capitalization of $5.2B. Wall Street consensus targets $121.67 (6 analysts), implying a +46.0% move over the next 12 months. The stock is currently 20% below its 52-week high of $104.00, remaining 117.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$66.84M↓ | -$59.78M↓ | -$57.45M↑ | -$62.35M↓ | -$55.51M |
| Net Income | -$65.64M↓ | -$58.16M↓ | -$56.74M↑ | -$61.46M↓ | -$54.31M |
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular end...